Freenome, Inc. (FRNM) Stock

NASDAQ: FRNMHealthcare company in the diagnostics & research industry, based in Brisbane, CA.

Freenome stock price chart

FRNM interactive chart →

FRNM stock quote & key statistics

Freenome earnings per share

Income →
Earnings per share

Freenome revenue & net income

Income →
RevenueNet income

Freenome annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$30.4M-$219.3M$0.08
FY2024$2.9M-$274.4M$0.17

Fiscal year ending December 31. Source: company filings via EODHD.

About Freenome, Inc.

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen" CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Freenome stock FAQ

What is the Freenome stock ticker symbol?

Freenome, Inc. trades on the NASDAQ under the ticker symbol FRNM.

What sector and industry is Freenome in?

Freenome, Inc. is classified in the Healthcare sector, Diagnostics & Research industry.

How many employees does Freenome have?

Freenome, Inc. has about 375 full-time employees.

What were Freenome's revenue and earnings last fiscal year?

Freenome reported revenue of $30.4M and net income of -$219.3M in fiscal 2025, with earnings per share of $0.08. Revenue grew 955.1% from the prior year.

When did Freenome go public?

Freenome stock began trading on July 20, 2026.

Diagnostics & Research stocks

All Healthcare stocks →